Telmisartan

At latest update, relevant published data on excretion into breast milk were not found.

Because of a high protein-binding capacity, a significant excretion into breast milk is unlikely.

However, it is one among the Sartan drugs (ARA-II type) with the longest half-life and highest oral bioavailability. The latter properties make it less convenient for use while breastfeeding.

Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken Telmisartan during pregnancy.

Until more data on this medication is available safer alternative drugs are preferred especially in premature babies or during the neonatal period.

Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan.

Alternatives

• Captopril (Very Low Risk)
• Enalapril (Very Low Risk)
• Quinapril Hydrochloride (Very Low Risk)